Newsbenzinga
FDA Clears First Targeted Dermatomyositis Treatment From Roivant
· Published
Article summary
FDA approves Roivant's LISRAYA for adult dermatomyositis, offering a once-daily targeted therapy that reduces steroid dependency.
An excerpt from the original article.
Comments —
Loading comments…